Drugs / THR-687
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03666923 | Sep 2018 → Nov 2019 | diabetes mellitus, diabetic macular edema | ThromboGenics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05063734 | Aug 2021 → Jun 2022 | diabetes mellitus, diabetic macular edema | Oxurion | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THR-687 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05063734 ↗ |
| Route | Intravitreal | “single intravitreal injection of THR-687 dose level 1” NCT03666923 ↗ |